|

REGN4336 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Regeneron Pharmaceuticals1

Indications

  • Metastatic Castration-resistant Prostate Cancer1
  • Cancer1

Palo Alto, California1 trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Stanford University Medical Center - Blake Wilbur Drive

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.